Zobrazeno 1 - 10
of 6 612
pro vyhledávání: '"S Agarwala"'
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, Marc S. Ernstoff, Bernard A. Fox, Thomas F. Gajewski, Jérôme Galon, Claus Garbe, Brian R. Gastman, Jeffrey E. Gershenwald, Pawel Kalinski, Michelle Krogsgaard, Rom S. Leidner, Roger S. Lo, Alexander M. Menzies, Olivier Michielin, Poulikos I. Poulikakos, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) o
Externí odkaz:
https://doaj.org/article/06bb97ac823040b3bb11134f118a0c11
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Christian Blank, Corrado Caracò, Richard D. Carvajal, Marc S. Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Jean-Jacques Grob, Omid Hamid, Michelle Krogsgaard, Roger S. Lo, Amanda W. Lund, Gabriele Madonna, Olivier Michielin, Bart Neyns, Iman Osman, Solange Peters, Poulikos I. Poulikakos, Sergio A. Quezada, Bradley Reinfeld, Laurence Zitvogel, Igor Puzanov, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-21 (2022)
Abstract Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has result
Externí odkaz:
https://doaj.org/article/eceaa54ada8b4252a49fcbe967456d2a
Autor:
Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Christian Blank, Richard D. Carvajal, Sandra Demaria, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Roger S. Lo, Georgina V. Long, Jason J. Luke, Iman Osman, Michael A. Postow, Ryan J. Sullivan, Janis M. Taube, Giorgio Trinchieri, Hassane M. Zarour, Corrado Caracò, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-22 (2020)
Abstract The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly impr
Externí odkaz:
https://doaj.org/article/f2b099b821ea4c5eaa13a1fff3485d97
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Alexander Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Olivier Michielin, Michael Postow, Igor Puzanov, Hassane M. Zarour, Corrado Caracò, Alessandro Testori
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-15 (2020)
Abstract The Great Debate session at the 2019 Melanoma Bridge congress (December 5-7, Naples, Italy) featured counterpoint views from experts on five topical issues in melanoma. These were whether to choose local intratumoral treatment or systemic tr
Externí odkaz:
https://doaj.org/article/4daede7f31dc4fb49579ddcb6b1f76b4
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Gerardo Botti, Alfredo Budillon, Michael A. Davies, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Silvia Formenti, Thomas F. Gajewski, Claus Garbe, Omid Hamid, Roger S. Lo, Jason J. Luke, Oliver Michielin, Giuseppe Palmieri, Laurence Zitvogel, Francesco M. Marincola, Giuseppe Masucci, Corrado Caracò, Magdalena Thurin, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-18 (2019)
Abstract Diagnosis of melanocytic lesions, correct prognostication of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to a given therapy remain very real challenges in melanoma. Recent studies have shown
Externí odkaz:
https://doaj.org/article/f27d29ec50b04d268fc157d83fd8e820
Autor:
W. Blauth
Publikováno v:
Orthopaedics and Traumatology. 9:228-229
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63d40c1e55d2e3b817f70f0a045afe26
https://doi.org/10.1007/s065-001-8357-7
https://doi.org/10.1007/s065-001-8357-7
Autor:
Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung, David H. Lawson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Abstract Background Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in p
Externí odkaz:
https://doaj.org/article/5cdc7070ed8046e696ecf169baa8612b
Autor:
Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Carlo Bifulco, Gerardo Botti, Corrado Caracò, Gennaro Ciliberto, Michael A. Davies, Reinhard Dummer, Soldano Ferrone, Thomas F. Gajewski, Claus Garbe, Jason J. Luke, Francesco M. Marincola, Giuseppe Masucci, Janice M. Mehnert, Nicola Mozzillo, Giuseppe Palmieri, Michael A. Postow, Stephen P. Schoenberger, Ena Wang, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-13 (2018)
Abstract Metastatic melanoma represents a challenging clinical situation and, until relatively recently, there was an absence of effective treatment options. However, in 2011, the advanced melanoma treatment landscape was revolutionised with the appr
Externí odkaz:
https://doaj.org/article/2d1e71fc5d4043f99a44acdb17e481d6
Autor:
Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards, Krista M. Rubin, William Sharfman, Steven Silverstein, Craig L. Slingluff, Vernon K. Sondak, Ahmad A. Tarhini, John A. Thompson, Walter J. Urba, Richard L. White, Eric D. Whitman, F. Stephen Hodi, Howard L. Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-23 (2018)
Abstract Background Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination re
Externí odkaz:
https://doaj.org/article/4608673a241f46ca9625955f197bdebe
Autor:
Drew W. Rasco, Theresa Medina, Pippa Corrie, Anna C. Pavlick, Mark R. Middleton, Paul Lorigan, Chris Hebert, Ruth Plummer, James Larkin, Sanjiv S. Agarwala, Adil I. Daud, Jiaheng Qiu, Viviana Bozon, Michelle Kneissl, Elly Barry, Anthony J. Olszanski
Publikováno v:
Cancer chemotherapy and pharmacology, vol 92, iss 1
Purpose Genomic alterations of BRAF and NRAS are oncogenic drivers in malignant melanoma and other solid tumors. Tovorafenib is an investigational, oral, selective, CNS-penetrant, small molecule, type II pan‑RAF inhibitor. This first-in-human phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6be879ecf897194f5e93f0a32cbcfa4d
https://www.repository.cam.ac.uk/handle/1810/350906
https://www.repository.cam.ac.uk/handle/1810/350906
